Abstract
Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.
| Original language | English |
|---|---|
| Pages (from-to) | 442-446 |
| Number of pages | 5 |
| Journal | American Journal of Kidney Diseases |
| Volume | 41 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2003 |
Fingerprint
Keywords
- Cardiovascular
- Dialysis
- Homocysteine
- N-Acetylcysteine (NAC)
ASJC Scopus subject areas
- Nephrology
Cite this
The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis : A randomized, controlled study. / Friedman, Allon; Bostom, Andrew G.; Laliberty, Priscilla; Selhub, Jacob; Shemin, Douglas.
In: American Journal of Kidney Diseases, Vol. 41, No. 2, 01.02.2003, p. 442-446.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis
T2 - A randomized, controlled study
AU - Friedman, Allon
AU - Bostom, Andrew G.
AU - Laliberty, Priscilla
AU - Selhub, Jacob
AU - Shemin, Douglas
PY - 2003/2/1
Y1 - 2003/2/1
N2 - Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.
AB - Background: The chronic hemodialysis population has an accelerated rate of cardiovascular morbidity and death. Furthermore, elevated levels of the putative atherothrombotic risk factor homocysteine are almost ubiquitous in this population. Attempts to normalize elevated plasma total homocysteine (tHcy) levels in dialysis patients using pharmacological-dose vitamin therapy or other strategies generally have been unsuccessful. Preliminary uncontrolled evidence suggests that N-acetylcysteine (NAC) may be an effective tHcy-lowering agent. We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients. Methods: Thirty-eight subjects were treated before intervention with a standard dialysis vitamin supplement to ensure a uniform vitamin-replete state. They were then block randomized to treatment with NAC, 1.2 g twice a day, for 4 weeks or matched placebo. Results: There were no significant baseline differences between the two groups, although differences in pyridoxal 5′-phosphate (active form of vitamin B6) levels approached significance (P = 0.06). In a paired analysis, there was no statistically significant difference between the NAC and placebo groups. NAC was very well tolerated in hemodialysis patients. Conclusion: This randomized placebo-controlled trial found that chronic oral NAC therapy did not significantly reduce tHcy levels in hemodialysis patients. Although a larger sample size theoretically could have increased the statistical significance between groups, implications of the potentially very modest reduction in tHcy levels are not yet known. Finally, based on this limited study, NAC appears to be a safe and well-tolerated therapy in the hemodialysis population.
KW - Cardiovascular
KW - Dialysis
KW - Homocysteine
KW - N-Acetylcysteine (NAC)
UR - http://www.scopus.com/inward/record.url?scp=0037308180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037308180&partnerID=8YFLogxK
U2 - 10.1053/ajkd.2003.50054
DO - 10.1053/ajkd.2003.50054
M3 - Article
C2 - 12552508
AN - SCOPUS:0037308180
VL - 41
SP - 442
EP - 446
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
SN - 0272-6386
IS - 2
ER -